← Leaderboards
Athanassios Argiris
Northwestern University
$721,909
Attributed
$721,909
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $345K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$721,909 · 3
By mechanism
R21$675,663 · 1
M01$46,246 · 2
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Chad A. Mirkin$20,335,625
- Amy Beth Heimberger$11,078,637
- Halcyon G Skinner$1,571,566
- Andrew M Evens$3,800,221
- Adam Brian Braunschweig$101,356
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationHead And Neck Squamous Cell CarcinomaElderlyErbituxGene TherapyHead And Neck CancerDesignE-CadherinEpidermal Growth Factor ReceptorCetuximabChemotherapyCisplatinBiopsyGrowthCancer CellClinical TrialsBaseDoseC-Erbb-1 Proto-OncogenesEndoscopyCombined Modality TherapyCommon Terminology Criteria For Adverse EventsComorbidityHead And Neck Structure
Grant awards (6)
EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer$219,846
R21 · FY2009 · CA · contact PI
EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer$125,139
R21 · FY2009 · CA · contact PI
EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer$330,678
R21 · FY2008 · CA · contact PI
NU 01L2: PHASE I/II TRIAL OF WEEKLY IRINOTECAN AND DOCETAXEL IN ADVANCED NSCLC$2,763
M01 · FY2005 · RR
NU 02Z4: FISH ANALYSIS OF SPUTUM SAMPLES FOR THE DIAGNOSIS OF LUNG CANCER$1,841
M01 · FY2005 · RR
NU 01L2: Phase I/II Trial of Weekly Irinotecan and Docetaxel in Advanced NSCLC$41,642
M01 · FY2004 · RR